Rituximab serum concentrations during immunochemotherapy of follicular lymphoma

Rituximab serum concentrations during immunochemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response by Ulrich Jäger, Michael Fridrik, Markus Zeitlinger, Daniel Heintel, Georg Hopfinger, Sonja Burgstaller, Christine Mannhalter, Wilhelm Oberaigner, Edit Porpaczy, Cathrin Skrabs, Christine Einberger, Johannes Drach, Markus Raderer, Alexander Gaiger, Monique Putman, and Richard Greil haematol Volume 97(9): 1431 -1438 September 5, 2012 © 2012 by Ferrata Storti Foundation

Patients’ characteristics and clinical outcome. Ulrich Jäger et al. Haematologica 2012; 97: 1431 -1438 © 2012 by Ferrata Storti Foundation

Detailed pharmacokinetic profiling during R-FM induction and rituximab maintenance. Ulrich Jäger et al. Haematologica 2012; 97: 1431 -1438 © 2012 by Ferrata Storti Foundation

Association of rituximab trough levels with gender, quality of remission (complete (CR) vs. partial (PR)), progression-free survival (PFS) and clinical relapse. Ulrich Jäger et al. Haematologica 2012; 97: 1431 -1438 © 2012 by Ferrata Storti Foundation

Median rituximab Ctrough levels (ng/m. L) according to gender, bone marrow infiltration and clinical response. Ulrich Jäger et al. Haematologica 2012; 97: 1431 -1438 © 2012 by Ferrata Storti Foundation

Correlation with rituximab Ctrough during induction and maintenance. Ulrich Jäger et al. Haematologica 2012; 97: 1431 -1438 © 2012 by Ferrata Storti Foundation